potassium chloride has been researched along with Chorea in 2 studies
Potassium Chloride: A white crystal or crystalline powder used in BUFFERS; FERTILIZERS; and EXPLOSIVES. It can be used to replenish ELECTROLYTES and restore WATER-ELECTROLYTE BALANCE in treating HYPOKALEMIA.
potassium chloride : A metal chloride salt with a K(+) counterion.
Chorea: Involuntary, forcible, rapid, jerky movements that may be subtle or become confluent, markedly altering normal patterns of movement. Hypotonia and pendular reflexes are often associated. Conditions which feature recurrent or persistent episodes of chorea as a primary manifestation of disease are referred to as CHOREATIC DISORDERS. Chorea is also a frequent manifestation of BASAL GANGLIA DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The proposed pathogenesis of Sydenham's chorea (SC) is an autoantibody-mediated basal ganglia dysfunction." | 1.33 | Serum from Sydenham's chorea patients modifies intracellular calcium levels in PC12 cells by a complement-independent mechanism. ( Cardoso, F; Guimarães, MM; Romano-Silva, MA; Teixeira, AL, 2005) |
| "Delayed-onset generalized dystonia and choreoathetosis then appeared." | 1.28 | Delayed onset movement disorders as a complication of central pontine myelinolysis. ( Ferrer, X; Julien, J; Tison, FX, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Teixeira, AL | 1 |
| Guimarães, MM | 1 |
| Romano-Silva, MA | 1 |
| Cardoso, F | 1 |
| Tison, FX | 1 |
| Ferrer, X | 1 |
| Julien, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Antibiotic Treatment Trial for the PANDAS/PANS Phenotype[NCT01617083] | Phase 2 | 47 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The CYBOCS is a clinician rated, semi-structured interview for rating the severity of OCD (Scahill, et al., 1997). Total scores range from 0 to 50, with higher scores representing greater severity. The total score is comprised of two subscores, obsessions and compulsions, each with a range of 0-25. (NCT01617083)
Timeframe: Before and after 4 week randomization
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | After 4 week randomization | |
| Azithromycin | 29.49 | 20.53 |
| Placebo | 28.43 | 23.45 |
The CGI-S scale is a 7-point clinician rating of severity of psychopathology. Severity ratings range from 1 (no illness) to 7 (extremely severe). This instrument has been successfully used in treatment studies (Cook, et al., 2001; Storch, et al., 2007). (NCT01617083)
Timeframe: Before and after 4 week randomization
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | After 4 week randomization | |
| Azithromycin | 5.24 | 4.06 |
| Placebo | 5.00 | 4.93 |
The Screen for Childhood Anxiety-Related Emotional Disorders (SCARED) is a 41-item parent and participant-completed tool used to measure symptoms of anxiety, including the most common symptoms of panic/somatic, generalized anxiety, separation anxiety, social phobia, and school phobia. Scores range from 0-82, with higher scores indicating more severe symptoms.The child and parent versions of the SCARED have moderate parent-child agreement and good internal consistency, test-retest reliability, and discriminant validity; it is also sensitive to treatment response (Birmaher et al. 1999). The target population for this rating is 8-18 years of age (Birmaher et al. 1997). The parent and child version of the SCARED were administered before and after week 4 randomization. This measure is not validated for use in 4-7 year olds. (NCT01617083)
Timeframe: Before and after 4 week randomization
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | After 4 week randomization | |
| Azithromycin | 31.82 | 30.88 |
| Placebo | 20.43 | 21.97 |
2 other studies available for potassium chloride and Chorea
| Article | Year |
|---|---|
Serum from Sydenham's chorea patients modifies intracellular calcium levels in PC12 cells by a complement-independent mechanism.
Topics: Adolescent; Animals; Antibodies; Basal Ganglia; Calcium; Child; Chorea; Complement System Proteins; | 2005 |
Delayed onset movement disorders as a complication of central pontine myelinolysis.
Topics: Athetosis; Chorea; Demyelinating Diseases; Dystonia; Female; Follow-Up Studies; Humans; Hypokalemia; | 1991 |